DUSA Pharmaceuticals, Inc. (NASDAQ: DUSA) today reported financial results for the second quarter ended June 30, 2006. These results represent the first full quarter of integrated operations with Sirius Laboratories, Inc. following the merger. Revenue for the quarter was $6.6 million, compared to $2.2 million in the second quarter of 2005. Revenue for the six-months ended June 30, 2006 was $11.4 million, compared to $5.6 million in the comparable 2005 period. Revenue for the six-month period ended June 30, 2006 of $11.4 million matches DUSA’s full year 2005 revenue.
